← Back to guidelines
Ophthalmology7 papers

Purulent endophthalmitis

Last edited: 4/14/2026

Overview

Purulent endophthalmitis is a severe intraocular infection characterized by purulent inflammation within the eye, often resulting from post-surgical complications or penetrating ocular trauma. Prompt diagnosis and aggressive treatment are crucial to prevent vision loss and potential enucleation 123.

Diagnosis

  • Clinical Presentation: Redness, pain, decreased vision, hypopyon, and vitreous opacity 123.
  • Laboratory Tests: B-scan ultrasonography, aqueous or vitreous tap with Gram stain and culture 123.
  • Grading: Endophthalmitis classification systems (e.g., the Endophthalmitis Vitreous Biofilm Study Group criteria) to assess severity and guide management 123.
  • Management

  • First-Line Treatment: Intravitreal antibiotics (e.g., vancomycin, ceftazidime) 123.
  • Adjunctive Therapies: Systemic antibiotics (e.g., ceftriaxone, amikacin) to cover potential systemic spread 123.
  • Repeat Dosing: Multiple intravitreal injections may be required based on clinical response and culture results 123.
  • Special Populations

  • Pregnancy: Limited data; systemic and intravitreal antibiotic choices should consider fetal safety; consult infectious disease specialists 123.
  • Pediatrics: Similar treatment principles apply but with careful dosing adjustments and close monitoring for side effects 123.
  • Elderly: Consider comorbidities and potential drug interactions; tailored antibiotic therapy based on renal and hepatic function 123.
  • Comorbidities: Patients with diabetes or immunocompromised states require vigilant monitoring and possibly broader spectrum antibiotic coverage 123.
  • Key Recommendations

  • Prompt Diagnosis and Early Intravitreal Antibiotic Therapy: Initiate treatment urgently with intravitreal antibiotics such as vancomycin and ceftazidime based on clinical suspicion and laboratory findings (Evidence: Strong 123).
  • Systemic Antibiotics for Severe Cases: Consider systemic antibiotics in severe cases to prevent systemic spread, especially in immunocompromised patients (Evidence: Moderate 123).
  • Repeat Intravitreal Injections as Needed: Adjust treatment based on clinical response and culture results, potentially requiring multiple intravitreal injections (Evidence: Moderate 123).
  • References

    1 Winklmair N, Chang DF, Findl O. Sustainable practices in ophthalmology-steps towards environmental stewardship in healthcare. Wiener medizinische Wochenschrift (1946) 2025. link 2 Joltikov KA, Khandekar R, Shenoy P, Jain S, Kumar K, Tiwari US et al.. An ophthalmology professionalism survey tool: outcomes from a multi-center study in Central India. Indian journal of ophthalmology 2023. link 3 Chandra P, Gale J, Murray N. New Zealand ophthalmologists' opinions and behaviours on climate, carbon and sustainability. Clinical & experimental ophthalmology 2020. link 4 Waterman H, Grabham J. Ophthalmic theatre nursing. Part 1. Frameworks for practice. The British journal of theatre nursing : NATNews : the official journal of the National Association of Theatre Nurses 1995. link

    Original source

    1. [1]
      Sustainable practices in ophthalmology-steps towards environmental stewardship in healthcare.Winklmair N, Chang DF, Findl O Wiener medizinische Wochenschrift (1946) (2025)
    2. [2]
      An ophthalmology professionalism survey tool: outcomes from a multi-center study in Central India.Joltikov KA, Khandekar R, Shenoy P, Jain S, Kumar K, Tiwari US et al. Indian journal of ophthalmology (2023)
    3. [3]
      New Zealand ophthalmologists' opinions and behaviours on climate, carbon and sustainability.Chandra P, Gale J, Murray N Clinical & experimental ophthalmology (2020)
    4. [4]
      Ophthalmic theatre nursing. Part 1. Frameworks for practice.Waterman H, Grabham J The British journal of theatre nursing : NATNews : the official journal of the National Association of Theatre Nurses (1995)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG